US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US20060148725A1
(en)
*
|
2001-12-21 |
2006-07-06 |
The Miriam Hospital |
Selective 11beta HSD inhibitors and methods of use thereof
|
AU2002361861A1
(en)
*
|
2001-12-21 |
2003-07-30 |
Rhode Island Hospital |
SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
|
CA2478183C
(en)
|
2002-03-12 |
2010-02-16 |
Merck & Co. Inc. |
Substituted amides
|
AR040241A1
(es)
*
|
2002-06-10 |
2005-03-23 |
Merck & Co Inc |
Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
|
JO2397B1
(en)
*
|
2002-12-20 |
2007-06-17 |
ميرك شارب اند دوم كوربوريشن |
Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
|
WO2004065380A1
(en)
|
2003-01-14 |
2004-08-05 |
Arena Pharmaceuticals Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
US20060183897A1
(en)
*
|
2003-03-18 |
2006-08-17 |
Chakravarty Prasun K |
Biaryl substituted triazoles as sodium channel blockers
|
MY142651A
(en)
*
|
2003-03-18 |
2010-12-15 |
Merck Sharp & Dohme |
Biaryl substituted triazoles as sodium channel blockers
|
EP1624876A2
(en)
*
|
2003-04-29 |
2006-02-15 |
The Miriam Hospital |
Selective testicular 11beta-hsd inhibitors and methods of use thereof
|
US8026264B2
(en)
*
|
2003-05-29 |
2011-09-27 |
Merck Sharp And Dohme Corp. |
Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
|
EP1644375A2
(en)
|
2003-07-14 |
2006-04-12 |
Arena Pharmaceuticals, Inc. |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
SI1663185T1
(sl)
|
2003-09-22 |
2009-04-30 |
Onepharm Res & Dev Gmbh |
Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
|
US8415354B2
(en)
*
|
2004-04-29 |
2013-04-09 |
Abbott Laboratories |
Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
|
US7880001B2
(en)
*
|
2004-04-29 |
2011-02-01 |
Abbott Laboratories |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
|
US20100222316A1
(en)
|
2004-04-29 |
2010-09-02 |
Abbott Laboratories |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
|
WO2005113513A2
(en)
|
2004-05-12 |
2005-12-01 |
Chemocentryx |
Aryl sulfonamides
|
JP2008509146A
(ja)
*
|
2004-08-06 |
2008-03-27 |
メルク エンド カムパニー インコーポレーテッド |
11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのスルホニル化合物
|
EP1778229A4
(en)
*
|
2004-08-10 |
2009-06-17 |
Incyte Corp |
AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
|
GB0418877D0
(en)
*
|
2004-08-24 |
2004-09-29 |
Univ Edinburgh |
Heart
|
CN101014578B
(zh)
*
|
2004-09-16 |
2011-01-19 |
安斯泰来制药有限公司 |
三唑衍生物或其盐
|
WO2006034056A2
(en)
*
|
2004-09-16 |
2006-03-30 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
BRPI0517148A
(pt)
|
2004-12-06 |
2008-09-30 |
Univ California |
método de aperfeiçoamento da estrutura e/ou função arterìola; agente ativo e kit para tratamento
|
JP4966202B2
(ja)
|
2004-12-24 |
2012-07-04 |
スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド |
治療または予防のための方法
|
US20090192198A1
(en)
|
2005-01-05 |
2009-07-30 |
Abbott Laboratories |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
|
MX2007008238A
(es)
|
2005-01-05 |
2007-08-17 |
Abbott Lab |
Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
|
NZ555971A
(en)
*
|
2005-01-05 |
2011-01-28 |
Abbott Lab |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
|
US8198331B2
(en)
*
|
2005-01-05 |
2012-06-12 |
Abbott Laboratories |
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
|
MY148521A
(en)
*
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
KR100979577B1
(ko)
*
|
2005-03-03 |
2010-09-01 |
에프. 호프만-라 로슈 아게 |
2형 진성 당뇨병의 치료를 위한11-베타-하이드록시스테로이드 탈수소효소의 억제제로서1-설폰일-피페리딘-3-카복실산 아마이드 유도체
|
GB0506133D0
(en)
*
|
2005-03-24 |
2005-05-04 |
Sterix Ltd |
Compound
|
US20100120789A1
(en)
*
|
2005-03-24 |
2010-05-13 |
Nigel Vicker |
Compound
|
US7759339B2
(en)
|
2005-03-31 |
2010-07-20 |
Takeda San Diego, Inc. |
Hydroxysteroid dehydrogenase inhibitors
|
RU2381217C2
(ru)
|
2005-04-05 |
2010-02-10 |
Ф.Хоффман-Ля Рош Аг |
Пиразолы
|
WO2006132197A1
(ja)
*
|
2005-06-07 |
2006-12-14 |
Shionogi & Co., Ltd. |
I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
|
US7579360B2
(en)
|
2005-06-09 |
2009-08-25 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US7572807B2
(en)
|
2005-06-09 |
2009-08-11 |
Bristol-Myers Squibb Company |
Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
|
WO2006134604A1
(en)
*
|
2005-06-15 |
2006-12-21 |
Hetero Drugs Limited |
Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
|
US7622492B2
(en)
|
2005-08-31 |
2009-11-24 |
Hoffmann-La Roche Inc. |
Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
CN103724335A
(zh)
*
|
2005-10-20 |
2014-04-16 |
默沙东公司 |
用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物
|
EP1973915A4
(en)
*
|
2006-01-13 |
2010-08-25 |
Merck Sharp & Dohme |
TRIAZONE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
|
KR101081293B1
(ko)
|
2006-01-18 |
2011-11-08 |
에프. 호프만-라 로슈 아게 |
11 베타-에이치에스디1 억제제로서 티아졸
|
WO2007088895A1
(ja)
*
|
2006-01-31 |
2007-08-09 |
Mochida Pharmaceutical Co., Ltd. |
3-アリールアミノ-1,2,4-トリアゾール誘導体
|
ZA200807451B
(en)
*
|
2006-03-16 |
2010-01-27 |
Astellas Pharma Inc |
A triazole derivative or salt thereof
|
JP5230595B2
(ja)
*
|
2006-03-20 |
2013-07-10 |
スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド |
炎症性疼痛の治療または予防の方法
|
EP2006286A4
(en)
|
2006-03-30 |
2010-04-07 |
Shionogi & Co |
ISOXAZOLE DERIVATIVE AND ISOTHIAZONE DERIVATIVITY WITH ANTICIPATING EFFECT ON 11 TYPE I BETA HYDROXYSTEROIDDEHYDROGENASE
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
NZ574759A
(en)
*
|
2006-07-14 |
2010-10-29 |
Chemocentryx Inc |
Triazolyl phenyl benzenesulfonamides
|
JP5320291B2
(ja)
*
|
2006-07-14 |
2013-10-23 |
ケモセントリックス, インコーポレイテッド |
トリアゾリルピリジルベンゼンスルホンアミド類
|
US7718683B2
(en)
|
2006-07-14 |
2010-05-18 |
Chemocentryx, Inc. |
Triazolyl phenyl benzenesulfonamides
|
AU2007283113A1
(en)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
CA2770486C
(en)
|
2006-09-22 |
2014-07-15 |
Merck Sharp & Dohme Corp. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
DE102006058207A1
(de)
*
|
2006-12-11 |
2008-06-19 |
Universitätsklinikum Schleswig-Holstein |
Verfahren zur Herstellung spezifischer Inhibitoren der 11beta-Hydroxysteroid-Dehydrogenase Typ 1 mit Nor-Oleanan- oder Nor-Ursan-Grundgerüsten
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
EP2136803B1
(en)
*
|
2007-04-18 |
2012-05-02 |
Merck Sharp & Dohme Corp. |
Triazole derivatives which are smo antagonists
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
JP5736098B2
(ja)
|
2007-08-21 |
2015-06-17 |
アッヴィ・インコーポレイテッド |
中枢神経系障害を治療するための医薬組成物
|
CA2697957A1
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
EP2682400B1
(en)
*
|
2007-08-28 |
2017-09-20 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
US8119658B2
(en)
|
2007-10-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
SI2298747T1
(sl)
|
2008-07-03 |
2017-08-31 |
Astellas Pharma Inc. |
Derivat triazola ali njegova sol
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
NZ592544A
(en)
|
2008-10-30 |
2013-01-25 |
Merck Sharp & Dohme |
Isonicotinamide orexin receptor antagonists
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
CA2743489A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
WO2010068580A1
(en)
|
2008-12-12 |
2010-06-17 |
Merck Sharp & Dohme Corp. |
Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
|
ES2350077B1
(es)
|
2009-06-04 |
2011-11-04 |
Laboratorios Salvat, S.A. |
Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011508A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
US8552022B2
(en)
|
2009-08-13 |
2013-10-08 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2470552B1
(en)
|
2009-08-26 |
2013-11-13 |
Sanofi |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
CA2771352A1
(en)
|
2009-09-02 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
EP3378854B1
(en)
|
2010-01-27 |
2022-12-21 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
WO2011103256A1
(en)
|
2010-02-22 |
2011-08-25 |
Merck Sharp & Dohme Corp. |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
JP5655633B2
(ja)
|
2010-03-04 |
2015-01-21 |
セントラル硝子株式会社 |
パーフルオロアルカンスルフィン酸塩の製造方法
|
WO2011146358A1
(en)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
UA112418C2
(uk)
|
2010-09-07 |
2016-09-12 |
Астеллас Фарма Інк. |
Терапевтичний болезаспокійливий засіб
|
PE20131371A1
(es)
|
2010-09-22 |
2013-11-25 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
US8710050B2
(en)
|
2011-03-08 |
2014-04-29 |
Sanofi |
Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
EP2693882B1
(en)
|
2011-04-08 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
US20140088124A1
(en)
|
2011-06-02 |
2014-03-27 |
Robert J. DeVita |
Imidazole derivatives
|
CA2838079A1
(en)
|
2011-06-16 |
2012-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2760855B1
(en)
|
2011-09-30 |
2017-03-15 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
WO2013062838A1
(en)
|
2011-10-24 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as gpr119 agonists
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
WO2013074388A1
(en)
|
2011-11-15 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
WO2013155600A1
(en)
|
2012-04-16 |
2013-10-24 |
Kaneq Pharma |
Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
|
WO2014018350A1
(en)
|
2012-07-23 |
2014-01-30 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-iv inhibitors
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
US10065945B2
(en)
|
2014-01-24 |
2018-09-04 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as MGAT2 inhibitors
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
EP3177287B1
(en)
|
2014-08-08 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
SG11201703238TA
(en)
|
2014-10-24 |
2017-05-30 |
Merck Sharp & Dohme |
Co-agonists of the glucagon and glp-1 receptors
|
CA3002540C
(en)
|
2015-01-06 |
2023-11-07 |
Arena Pharmaceuticals, Inc. |
Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
|
AU2016284162A1
(en)
|
2015-06-22 |
2018-02-01 |
Arena Pharmaceuticals, Inc. |
Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
|
WO2017062334A1
(en)
|
2015-10-05 |
2017-04-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
EP3235813A1
(en)
|
2016-04-19 |
2017-10-25 |
Cidqo 2012, S.L. |
Aza-tetra-cyclo derivatives
|
TW201808888A
(zh)
*
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
TW201808914A
(zh)
*
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
TW201808903A
(zh)
|
2016-05-05 |
2018-03-16 |
嘉來克生命科學有限責任公司 |
整合應激途徑之調節劑
|
WO2017205425A1
(en)
*
|
2016-05-24 |
2017-11-30 |
President And Fellows Of Harvard College |
Compounds for organic light emitting diode materials
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
EP3496716B1
(en)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
EP3496715B1
(en)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
CN110520124A
(zh)
|
2017-02-16 |
2019-11-29 |
艾尼纳制药公司 |
用于治疗原发性胆汁性胆管炎的化合物和方法
|
SG11202000532SA
(en)
|
2017-08-09 |
2020-02-27 |
Denali Therapeutics Inc |
Compounds, compositions and methods
|
TWI802591B
(zh)
*
|
2017-09-14 |
2023-05-21 |
日商第一三共股份有限公司 |
具有環狀構造的化合物
|
MX2020004519A
(es)
*
|
2017-11-02 |
2020-11-09 |
Calico Life Sciences Llc |
Moduladores de la vía de estrés integrada.
|
BR112020008827A2
(pt)
*
|
2017-11-02 |
2020-10-20 |
Calico Life Sciences Llc |
moduladores da via de estresse integrada
|
CN112166113A
(zh)
|
2017-11-02 |
2021-01-01 |
卡里科生命科学有限责任公司 |
整合应激通路的调节剂
|
TWI771621B
(zh)
|
2018-10-11 |
2022-07-21 |
美商嘉來克生命科學有限責任公司 |
整合應激路徑之前藥調節劑
|
AU2020223228A1
(en)
|
2019-02-13 |
2021-08-26 |
Denali Therapeutics Inc. |
Compounds, compositions and methods
|
EP3924058A1
(en)
|
2019-02-13 |
2021-12-22 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
EP3842060A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled lactam co-agonists of the glucagon and glp-1 receptors
|
EP3842061A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled triazole co-agonists of the glucagon and glp-1 receptors
|
EP3842449A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled olefin co-agonists of the glucagon and glp-1 receptors
|
CN116249697A
(zh)
|
2020-08-18 |
2023-06-09 |
默沙东有限责任公司 |
二环庚烷吡咯烷食欲素受体激动剂
|